Profiles of Patients Who Initiated Brolucizumab for Neovascular (Wet) Age-related Macular Degeneration in the IRIS Registry

Mathew MacCumber, M.D., Ph.D.
Chicago, IL

Justin Yu, PharmD, MD, Guru Prasad B, MBBS, MD, Xiaoyu Bi, PhD, Ngan Pham, PhD, Andrew LaPrise, Neetu Agashivala, BPharmacy, MS, Rishi P Singh, MD, Charles Wykoff, MD, PhD

Purpose:
The purpose of this study was to assess real-world baseline demographic and clinical characteristics of patients who initiated brolucizumab for neovascular (wet) age-related macular degeneration (AMD).

Methods:
Using the IRIS Registry, adult wet AMD patients with ≥1 brolucizumab injection from 10/08/2019 to 1/31/2020 were included in this study (earliest date of injection=index date). Patients were excluded if they had participated in a brolucizumab clinical trial or had unspecified wet AMD laterality on or prior to the index date. Patient demographic and clinical characteristics were assessed on the index date or prior to the index date. Demographic characteristics were assessed at the patient level and clinical characteristics were assessed at the patient eye level.

Results:
4,551 unique brolucizumab patient eyes, corresponding to 3,896 unique patients, were included in this study. The mean (standard deviation) age of the patients was 80.1 (8.3) years, 57.8% were female, and 83.2% had unilateral disease. Visual acuity (VA) on the index date or the 30 days prior was 20/12-20/20, 20/25-20/40, 20/50-20/160, and ≤20/200 for 6.2%, 43.0%, 39.8%, and 10.9% of patient eyes with non-missing VA data (n=3,377), respectively. 6.7% of patient eyes were naïve to anti-VEGF agents, while 93.3% of patient eyes were treated with another anti-VEGF agent prior to brolucizumab. Among the latter, the most recent anti-VEGF drug delivered to the patient eye prior to brolucizumab was aflibercept (71.0%) ranibizumab (14.5%), or bevacizumab (14.5%).

Conclusions:
The majority of wet AMD patients initiating brolucizumab switched from a prior anti-VEGF agent. Unmet needs continue to exist for many wet AMD patients, as demonstrated by switching to brolucizumab.